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nfection control to curb resistance in Asia
.H. Seto
Queen Mary Hopsital, Hong Kong, China
Antibiotics resistance is presently a worldwide problem includ-
ngAsia.Abrief reviewof thedifferent typesand their epidemiology
n Asia will be presented. In terms of prevention, a two-tier system
or infection control of multiple drug resistant organisms (MDROs)
s generally recommended as also by the CDC of USA. The system
ill bedescribed. In the second tierofpreventivemeasures, thepar-
icular measures must be selected based on the organism. Based on
he above preventive scheme, the three main problems in Asia will
e highlighted:
Insufﬁcient laboratory facilities for proper diagnosis of antimi-
robial resistance.Not implementing the core components for
nfection control.Meager national efforts to combat antimicrobial
esistance.
The MDR Gram-negative organisms are now the focus of global
ttention. In terms of the newer Gram-negative MDROs, this can
e difﬁcult because the epidemiology of the organisms is still
ot entirely clear. Furthermore the effectiveness of the different
icrobiology methods such as for screening and surveillance is not
ell deﬁned. Nevertheless an attempt will be made to present the
est possible infection control strategies for variousGram-negative
rganisms in the present context.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.011
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mplementing infection control in resource limited settings
. Mehta
Consultant WHO South East Asia Region, New Dehli, India
Implementing effective infection control in healthcare facili-
ies in resource poor settings in the developing world is a major
hallenge not only due to economic deﬁcits, but also because of
oorly placed and implemented systems including the purchase,
nventory and distribution of supplies, appropriatemanagement of
ealth technology, cleaning and sanitation and the management of
linical waste. Opposing traditional values contribute to the chal-
enge in these settings. The warm and tropical climate in many
eveloping countries encourages the survival of microorganisms.
ombined with low level of health care, hygiene, and sanitation
here is a relatively high transmission and prevalence of infec-
ions. Thus implementing good infection control in such situations
s complex and multifactorial.nfectious Diseases 16S (2012) e2–e157 e3
Of prime importance is capacity building in all its aspects. Edu-
cation and training is key. A health systems approach is essential
to make an impact. Efforts are required towards comprehensive
pre professional and post professional training of healthcare pro-
fessionals including the development of educational resources
that match the needs and address healthcare issues present in
resource poor settings. To conserve resources and eliminatewaste-
ful infection control practices it is necessary topromote operational
research to identify and prioritise effective infection control prac-
tices.
http://dx.doi.org/10.1016/j.ijid.2012.05.012
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Regional differences impacting infection control practices
B. Allegranzi
WHO, Geneva, Switzerland
The WHO “Clean Care is Safer Care” (CCiSC) programme,
launched in October 2005, aims at reducing healthcare-associated
infections (HAI) worldwide.To achieve its aim CCiSC have set 3
objectives: 1) to raise global awareness about the importance of
HAI; 2) to galvanize political commitment by Member States; 3) to
promote best practices at the point of care.
Implemented actions were: 1) networking and collaborations
with international experts and stakeholders; scientiﬁc publica-
tions; educational activities at national and international levels;
2) invitation to Ministries of Health to sign a formal statement
as a pledge of their commitment to tackle HAI; 3) development
and dissemination of guidelines and technical tools. Hand hygiene
(HH) promotion in healthcare settings (HCFs) has been the cor-
nerstone of CCiSC technical work. The feasibility and effectiveness
of the WHO HH Guidelines and its implementation strategies and
tools were tested in 8 pilot sites worldwide. The Save Lives: Clean
Your Hands (SLCYH) global initiative supports HCFs committed to
HH improvement. Systematic reviews andmeta-analysiswere con-
ducted to assess the epidemiological burden of endemic HAI in
developing countries.
Ministries of Health of 127 countries signed the WHO pledge to
reduce HAI and 45 launched national/sub-national HH campaigns.
According to the systematic reviews, hospital-wide HAI preva-
lence and HAI incidence in critically ill patients in developing
countries are at least 2-3 times higher compared to developed
countries; incidence of device-associated infections is 2 to 19 times
higher.
Following implementation of the WHO recommendations and
strategies, signiﬁcant increase of HH compliance and improvement
in infrastructure for HH and healthcare workers’ perception and
knowledge about the importance of HAI and HH were observed
across all pilot sites.
As ofApril 2012, 14409HCFs from150countries registered tobe
part of SLCYH. Among these, a recent survey of 2119 HCFs assessed
27 indicators related toHH implementationandhighlighted several
regional and country differences. The results will be presented.
National approaches to infection control and HH promotion in
different regions have been assessed. The examples of Australia,
e al of I
B
p
h
T
F
S
n
D
T
R
I
T
v
4
e
w
a
o
d
t
t
m
4
t
v
a
n
P
E
d
r
t
h
e
s
c
f
H
s
p
h
the potential economic value of introducing dengue vaccination in
South East Asia.4 15th ICID Abstracts / International Journ
razil, Saudi Arabia, Senegal, United Kingdom, Cambodia will be
resented.
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ntroduction on the global dengue epidemiological burden
. Chotpitayasunondh
Queen Sirikit National Institute of Child Health, Bangkok, Thailand
Dengue disease is the most rapidly spreading mosquito-borne
iral disease. Worldwide, between 2.5 and 3.6 billion people, over
0% of the population, are at risk, in over 100 endemic countries. An
stimated 50 to 100 million dengue infections occur every year, of
hich 2 million cases evolve to severe Dengue Hemorrhagic Fever,
nd 21 000 would result in death. Most severe disease and deaths
ccur in children. The rapid global spread of dengue is due to: 1)
emographic changes (i.e., population growth and land use pat-
erns); 2) increased urban population size and density due to rural
o urbanmigration 3)modern transportationwith increasedmove-
ent of people, commodities, animals, vectors and pathogens; and
) changes in public health policies and infrastructure among other
hings.
The geographic spread of both the mosquito vectors and the
iruses has led to a global resurgence of epidemic dengue disease
nd emergence of severe forms in the past 25 years. Dengue is
ow endemic in Asia, the Paciﬁc area, Africa, some parts of US (e.g.
uerto Rico), and Latin America (including the Caribbean). South-
ast Asia and the Western Paciﬁc Regions bear nearly 75% of the
engue global disease burden. In 2010, 187,333 dengue cases were
eported to the WHO SEA ofﬁce; and 354,009 cases were reported
o the WHO Western Paciﬁc Region. Efforts to control the vector
ave limited effect on the risk for disease in humans.
While geographical expansion of dengue and its vector are
vident, the true burden of disease is underestimated due to con-
traints inherent to public health surveillance systems and the
hallenges speciﬁc to dengue.
In the absence of an effective vaccine, public health systems
ocus on the early identiﬁcation and early response to outbreaks.
owever, once adiseasebecomesvaccinepreventable, surveillance
ystems become key tools to assess the performance of vaccination
rograms and need to be optimized to suit that purpose.
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Introduction on the global dengue epidemiological burden
Y.S. Leo
Communicable Disease Centre, Tan Tock Seng Hospital, Singapore,
Singapore
The WHO estimates that approximately 1.8 billion individuals
living in Southeast Asia andWestern Paciﬁc are at risk of dengue, ie,
nearly 75% of the current global dengue burden. Without anti-viral
drugs and vaccines, vector control has been the mainstay of pre-
vention against dengue. Resource-limited areas lacking sustainable
resources to combat the vector are badly hit by the rising number
of dengue cases.
It is worth noting that there are several studies in recently years
addressing dengue disease burden in anticipation of an approved
and available vaccine in the near future. A study conducted in 2005
suggested that the cost of dengue in 8 countries in the Americas
and Asia was at least 587 million international dollars. Adjusted for
under-reporting, the amount could rise to 1.8 billion international
dollars. A comprehensive systematic review and expert opinions
underlined the difﬁculties in estimating disease burden across the
globe and in different period of assessment such as using only DHF
incidence inestimatingDALY in theearlier studies, under-reporting
of non-hospitalized dengue fever cases, the inconsistent applica-
tion of disability score, etc. Recommendation was made to study
cost-effectiveness to avoid the inherent difﬁculties of cost-beneﬁt
analyses requiring conversion of beneﬁts into monetary units.
A study was done recently in Singapore to look at the economic
impact of dengue illness and the cost-effectiveness of future vac-
cination program. Singapore is a well developed city island state
located centrally in Southeast Asia, a dengue high burden region.
Paradoxical to the decline of vector density as a result of the inter-
nationally well-recognized vector control program, the country
experienced resurgent of dengue epidemics and on-going dengue
transmission. The study estimated an average economic impact of
dengue illness from 2000-2009 ranging between US$0.85 billion
and 1.15 billion, of which control costs constituted 42%-59%.
The substantial cost of dengue illness and prevention indicateshttp://dx.doi.org/10.1016/j.ijid.2012.05.015
